secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001437749-24-024543
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA panel votes 11-5 that Zevra's arimoclomol is effective for NPC; PDUFA date Sep 21
--------------------------------------------------------------------------------

- FDA GeMDAC voted 11 yes, 5 no that data support arimoclomol as effective for Niemann-Pick disease type C.
- PDUFA action date for arimoclomol NDA is September 21, 2024.
- The committee’s recommendation is non-binding but will be considered by the FDA.
- Vote based on pivotal trial, long-term open-label extension, and expanded access program data.
- Zevra CEO expresses confidence in arimoclomol's clinical benefit and path to approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924024543/0001437749-24-024543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924024543/zvra20240802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-024543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer